Cell Therapeutics is selling off the remaining 50% stake in its cancer drug Zevalin for $18 million in a desperate bid to keep the company afloat.
More: continued here
Cell Therapeutics is selling off the remaining 50% stake in its cancer drug Zevalin for $18 million in a desperate bid to keep the company afloat.
More: continued here